cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2023.8.n2530cardio-2530Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL CASE REPORTКлинический случай применения экзогенного фосфокреатина у пациентки с хронической сердечной недостаточностью с сохраненной фракцией выброса левого желудочкаThe Article Presents a Clinical Case of Successful Use of Neoton in a Patient With Decompensated Chronic Heart Failurehttps://orcid.org/0000-0001-9234-6129ТерещенкоС. Н.TereschenkoS. N.

д-р мед. наук, проф., рук-ль отд. заболеваний миокарда и сердечной недостаточности. 

 

doctor of medicine, professor, head of the Department of myocardial diseases and heart failure 

stereschenko@yandex.ruhttps://orcid.org/0000-0003-3483-4698СафиуллинаА. А.SafiulinaA. A.

канд. мед. наук, науч. сотр. отд. заболеваний миокарда и сердечной недостаточности

 

 

Phd

a_safiulina@mail.ruФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е. И. Чазова» Минздрава России, МоскваРоссияChazov National Medical Research Center of Cardiology, MoscowRussian Federation2023310820236386267Copyright © Kardiomag, 20232023KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/2530

В статье представлен клинический случай успешного применения неотона у пациентки с декомпенсацией хронической сердечной недостаточности с сохраненной фракцией выброса левого желудочка. Инфузия неотона продемонстрировала улучшение клинико-функционального статуса, снижение концентрации N-концевого фрагмента предшественника мозгового натрийуретического пептида (NT-proBNP) и улучшение диастолической функции левого желудочка.

The article presents a clinical case of successful Neoton treatment of a patient with decompensated chronic heart failure with preserved left ventricular ejection fraction. Neoton infusion induced an improvement in the clinical and functional status, a decrease in N-terminal pro-brain natriuretic peptide (NT-proBNP), and an improvement in left ventricular diastolic function.

 

Хроническая сердечная недостаточностьлевый желудочексохраненная фракция выбросаэкзогенный фосфокреатинChronic heart failureleft ventriclepreserved ejection fractionexogenous phosphocreatineАльфасигма Рус. Конфликт интересов не заявлен.No conflict of interest is reported.ReferencesSavarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 2023;118(17):3272–87. DOI: 10.1093/cvr/cvac013Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 2023;118(17):3272–87. DOI: 10.1093/cvr/cvac013Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. Journal of the American College of Cardiology. 2017;70(20):2476–86. DOI: 10.1016/j.jacc.2017.08.074Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. Journal of the American College of Cardiology. 2017;70(20):2476–86. DOI: 10.1016/j.jacc.2017.08.074Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis. European Journal of Heart Failure. 2019;21(11):1306–25. DOI: 10.1002/ejhf.1594Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis. European Journal of Heart Failure. 2019;21(11):1306–25. DOI: 10.1002/ejhf.1594Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2018;20(5):853–72. DOI: 10.1002/ejhf.1170Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2018;20(5):853–72. DOI: 10.1002/ejhf.1170McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 2022;24(1):4– 131. DOI: 10.1002/ejhf.2333McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 2022;24(1):4– 131. DOI: 10.1002/ejhf.2333Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385(16):1451–61. DOI: 10.1056/NEJMoa2107038Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385(16):1451–61. DOI: 10.1056/NEJMoa2107038Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. DOI: 10.1161/CIR.0000000000001063Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. DOI: 10.1161/CIR.0000000000001063Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2023;81(18):1835–78. DOI: 10.1016/j.jacc.2023.03.393Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL et al. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2023;81(18):1835–78. DOI: 10.1016/j.jacc.2023.03.393Dai D-F, Chen T, Szeto H, Nieves-Cintrón M, Kutyavin V, Santana LF et al. Mitochondrial Targeted Antioxidant Peptide Ameliorates Hypertensive Cardiomyopathy. Journal of the American College of Cardiology. 2011;58(1):73–82. DOI: 10.1016/j.jacc.2010.12.044Dai D-F, Chen T, Szeto H, Nieves-Cintrón M, Kutyavin V, Santana LF et al. Mitochondrial Targeted Antioxidant Peptide Ameliorates Hypertensive Cardiomyopathy. Journal of the American College of Cardiology. 2011;58(1):73–82. DOI: 10.1016/j.jacc.2010.12.044Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L et al. Heart Failure With Preserved Ejection Fraction Is Characterized by Dynamic Impairment of Active Relaxation and Contraction of the Left Ventricle on Exercise and Associated With Myocardial Energy Deficiency. Journal of the American College of Cardiology. 2009;54(5):402–9. DOI: 10.1016/j.jacc.2009.05.012Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L et al. Heart Failure With Preserved Ejection Fraction Is Characterized by Dynamic Impairment of Active Relaxation and Contraction of the Left Ventricle on Exercise and Associated With Myocardial Energy Deficiency. Journal of the American College of Cardiology. 2009;54(5):402–9. DOI: 10.1016/j.jacc.2009.05.012Bhella PS, Prasad A, Heinicke K, Hastings JL, Arbab-Zadeh A, Adams-Huet B et al. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. European Journal of Heart Failure. 2011;13(12):1296–304. DOI: 10.1093/eurjhf/hfr133Bhella PS, Prasad A, Heinicke K, Hastings JL, Arbab-Zadeh A, AdamsHuet B et al. Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction. European Journal of Heart Failure. 2011;13(12):1296–304. DOI: 10.1093/eurjhf/hfr133Терещенко С.Н., Черемисина И.А., Сафиуллина А.А. Эффективность неотона у больных с хронической сердечной недостаточностью в зависимости от фракции выброса левого желудочка. Субанализ исследования BYHEART. Российский кардиологический журнал. 2022;27(11):57-67. DOI: 10.15829/1560-4071-2022-5276Tereshchenko S.N., Cheremisina I.A., Safiullina A.A. Effectiveness of neoton in patients with chronic heart failure depending on the left ventricular ejection fraction. Sub-analysis of the BYHEART study. Russian Journal of Cardiology. 2022;27(11):57–67. DOI: 10.15829/1560-4071-2022-5276Терещенко С.Н., Черемисина И.А., Сафиуллина А.А. Возможности улучшения терапии хронической сердечной недостаточности по результатам многоцентрового наблюдательного исследования BYHEART. Терапевтический архив. 2022;94(4):517-23. DOI: 10.26442/00403660.2022.04.201450Tereshchenko S.N., Cheremisina I.A., Safiullina A.A. The possibilities of improving the treatment of chronic heart failure according to the results of a multicenter observational study BYHEART. Therapeutic Archive. 2022;94(4):517–23. DOI: 10.26442/00403660.2022.04.201450Михин В.П., Николенко Т.А., Громнацкий Н.И. Эффективность креатинфосфата в составе комплексной терапии у больных с хронической сердечной недостаточностью, перенесших инфаркт миокарда с подъемом сегмента ST. Лечебное дело. 2020;1:64-70. DOI: 10.24411/2071-5315-2020-12194Mikhin V.P., Nikolenko T.A., Gromnatskiy N.I. The Efficacy of Creatine Phosphate as Part of Complex Therapy in Patients with Chronic Heart Failure and History of ST-elevation Myocardial Infarction. Medical business. 2020;1:64–70. DOI: 10.24411/2071-5315-2020-12194Ковалев С.А., Белов В.Н., Осипова О.А. Эффективность фосфокреатина у больных ишемической болезнью сердца и сердечной недостаточностью после хирургической реваскуляризации миокарда. Вестник экспериментальной и клинической хирургии. 2015;8(4):314-17Kovalev S.A., Belov V.N., Osipova O.A. Effectiveness of phosphocreatine in patients with ischemic heart disease and heart failure after surgical revascularization. Journal of Experimental and Clinical Surgery. 2015;8(4):314–7.Симаков А.А., Поляева Л.В., Рязанова Е.И. Пути оптимизации лечения больных хронической сердечной недостаточностью на фоне ишемической болезни сердца. Кардиология и сердечно-сосудистая хирургия. 2014;7(5):20-3Simakov A.A., Polyaeva L.V., Ryazanova E.I. Optimization of treatment of chronic heart failure in patients with ischemic heart disease. Cardiology and Cardiovascular Surgery. 2014;7(5):20–3.Saks V.A., Kapelko V.I., Ruda M.Y., Semenovski M.L., Strumia E. Phosphocreatine as effective drug in clinical cardiology. P. 239-248. In: Guanidino compounds in biology and medicine. Deyn PP de, editor -London: J. Libbey;1992. - 480 p. ISBN 978-0-86196-330-0Saks V.A., Kapelko V.I., Ruda M.Y., Semenovski M.L., Strumia E. Phosphocreatine as effective drug in clinical cardiology. P. 239-248. In: Guanidino compounds in biology and medicine. Deyn PP de, editor -London: J. Libbey;1992. - 480 p. ISBN 978-0-86196-330-0Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297–317. DOI: 10.1093/eurheartj/ehz641Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297–317. DOI: 10.1093/eurheartj/ehz641Liu W, Qaed E, Zhu HG, Dong MX, Tang Z. Non-energy mechanism of phosphocreatine on the protection of cell survival. Biomedicine & Pharmacotherapy. 2021;141:111839. DOI: 10.1016/j.biopha.2021.111839Liu W, Qaed E, Zhu HG, Dong MX, Tang Z. Non-energy mechanism of phosphocreatine on the protection of cell survival. Biomedicine & Pharmacotherapy. 2021;141:111839. DOI: 10.1016/j.biopha.2021.111839Carmenini G, Giuliano G, Casaccio F, Migliau G. Controlled multicentric clinical study with placebo in patients with dilatative myocardiopathy functional class II‐III N.Y.H.A. treated with oral phosphocreatinine. Сuore rivista di cardiochirurgia e cardiologia. 1994;11(2):187‐193. [Av. at: https://www.researchgate.net/publication/297457856_Controlled_multicentric_clinical_study_with_placebo_in_patients_with_dilatative_myocardiopathy_functional_class_II-III_NYHA_treated_with_oral_phosphocreatinine]Carmenini G, Giuliano G, Casaccio F, Migliau G. Controlled multicentric clinical study with placebo in patients with dilatative myocardiopathy functional class II‐III N.Y.H.A. treated with oral phosphocreatinine. Сuore rivista di cardiochirurgia e cardiologia. 1994;11(2):187‐193. [Av. at: https://www.researchgate.net/publication/297457856_Controlled_multicentric_clinical_study_with_placebo_in_patients_with_dilatative_myocardiopathy_functional_class_II-III_NYHA_treated_with_oral_phosphocreatinine]Wang FR, Zheng X. Effects of phosphocreatine on plasma brain natriuretic peptide level and left ventricular function in patients with heart failure. Chinese Medicine University. 2008;16:29–31. [Published at PJCCPVD]Wang FR, Zheng X. Effects of phosphocreatine on plasma brain natriuretic peptide level and left ventricular function in patients with heart failure. Chinese Medicine University. 2008;16:29–31. [Published at PJCCPVD]Du X, Liang F, Zhao X. Effects of phosphocreatine on plasma brain natriuretic peptide level in elderly patients with chronic congestive heart failure. Journal of Southern Medical University. 2009;29(1):154–5, 159. PMID: 19218138Du X, Liang F, Zhao X. Effects of phosphocreatine on plasma brain natriuretic peptide level in elderly patients with chronic congestive heart failure. Journal of Southern Medical University. 2009;29(1):154–5, 159. PMID: 19218138Peng W. Clinical effect of sodium creatine phosphate in the treatment of chronic heart failure. Chinese Medicine. 2013;8(9). DOI: 10.3760/cma.j.issn.1673-4777.013.09.004Peng W. Clinical effect of sodium creatine phosphate in the treatment of chronic heart failure. Chinese Medicine. 2013;8(9). DOI: 10.3760/cma.j.issn.1673-4777.013.09.004Jing Z. Efficacy of sacubitril valsartan combined with sodium creatine phosphate in the treatment of chronic heart failure. Chinese Journal of Practical Medicine. 2020;47(18). DOI: 10.3760/cma.j.cn115689-20200604-02804Jing Z. Efficacy of sacubitril valsartan combined with sodium creatine phosphate in the treatment of chronic heart failure. Chinese Journal of Practical Medicine. 2020;47(18). DOI: 10.3760/cma.j.cn115689-20200604-02804Li XH, Xing YQ, Zhang X. Clinical efficacy of exogenous phosphocreatine in the treatment of elderly patients with chronic heart failure and its impact on heart failure markers. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease. 2020;28(6):42–6Li XH, Xing YQ, Zhang X. Clinical efficacy of exogenous phosphocreatine in the treatment of elderly patients with chronic heart failure and its impact on heart failure markers. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease. 2020;28(6):42–6Васюк Ю.А., Гендлин Г.Е., Емелина Е.И., Шупенина Е.Ю., Баллюзек М.Ф., Баринова И.В. и др. Согласованное мнение Российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой терапии. Российский кардиологический журнал. 2021;26(9):152-233. DOI: 10.15829/1560-4071-2021-4703Vasyuk Yu.A., Gendlin G.E., Emelina E.I., Shupenina E.Yu., Ballyuzek M.F., Barinova I.V. et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):152–233. DOI: 10.15829/1560-4071-2021-4703Заболотских И.Б., Баутин А.Е., Замятин М.Н., Лебединский К.М., Потиевская В.И., Трембач Н.В. Периоперационное ведение пациентов с хронической сердечной недостаточностью. Анестезиология и реаниматология. 2019;3:5-24. DOI: 10.17116/anaesthesiology20190315Zabolotskikh I.B., Bautin A.E., Zamyatin M.N., Lebedinskii K.M., Potievskaya V.I., Trembach N.V. Perioperative management of patients with chronic heart failure. Russian Journal of Anaesthesiology and Reanimatology. 2019;3:5–24. DOI: 10.17116/anaesthesiology20190315Заболотских И.Б., Киров М.Ю., Лебединский К.М., Проценко Д.Н., Авдеев С.Н., Андреенко А.А. и др. Анестезиолого-реанимационное обеспечение пациентов с новой коронавирусной инфекцией COVID-19. Методические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов». Вестник интенсивной терапии имени А.И. Салтанова. 2022;1:5-140. DOI: 10.21320/1818-474X-2022-1-5-140Zabolotskikh I.B., Kirov M.Yu., Lebedinskii K.M., Protsenko D.N., Avdeev S.N., Andreenko A.A. et al. Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. Annals of Critical Care. 2022;1:5–140. DOI: 10.21320/1818-474X-2022-1-5-140

The authors declare that there are no conflicts of interest present.